Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development

A. Hays, M. Wissel, K. Colletti, R. Soon, M. Azadeh, J. Smith, R. Doddareddy, M. Chalfant, W. Adamowicz, SS. Ramaswamy, SL. Dholakiya, S. Guelman, B. Gullick, J. Durham, K. Rennier, P. Nagilla, A. Muruganandham, M. Diaz, C. Tierney, K. John, J....

. 2024 ; 26 (1) : 24. [pub] 20240205

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007200

The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007200
003      
CZ-PrNML
005      
20240423155803.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1208/s12248-023-00880-9 $2 doi
035    __
$a (PubMed)38316745
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hays, Amanda $u BioAgilytix Laboratories, Durham, North Carolina, USA. amanda.hays@bioagilytix.com
245    10
$a Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development / $c A. Hays, M. Wissel, K. Colletti, R. Soon, M. Azadeh, J. Smith, R. Doddareddy, M. Chalfant, W. Adamowicz, SS. Ramaswamy, SL. Dholakiya, S. Guelman, B. Gullick, J. Durham, K. Rennier, P. Nagilla, A. Muruganandham, M. Diaz, C. Tierney, K. John, J. Valentine, T. Lockman, HY. Liu, B. Moritz, JP. Ouedraogo, MS. Piche, M. Smet, J. Murphy, K. Koenig, A. Zybura, C. Vyhlidal, J. Mercier, N. Jani, M. Kubista, D. Birch, K. Morse, O. Johansson
520    9_
$a The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies.
650    _2
$a tkáňová distribuce $7 D014018
650    12
$a vyvíjení léků $7 D000076722
650    12
$a genetická terapie $7 D015316
650    _2
$a polymerázová řetězová reakce $7 D016133
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wissel, Mark $u Eurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA
700    1_
$a Colletti, Kelly $u Beam Therapeutics, Cambridge, Massachusetts, USA
700    1_
$a Soon, Russell $u BioMarin Pharmaceutical Inc., Novato, California, USA
700    1_
$a Azadeh, Mitra $u Ultragenyx Pharmaceutical Inc., Novato, Calfornia, USA
700    1_
$a Smith, Justin $u Pfizer Inc, Groton, Connecticut, USA
700    1_
$a Doddareddy, Rajitha $u Merck & Co., Inc., Rahway, New Jersey, USA
700    1_
$a Chalfant, Melanie $u GSK, Collegeville, Pennsylvania, USA
700    1_
$a Adamowicz, Wendy $u PPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA
700    1_
$a Ramaswamy, Swarna Suba $u Eli Lilly and Company, Indianapolis, Indiana, USA
700    1_
$a Dholakiya, Sanjay L $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Guelman, Sebastian $u Genentech, Inc., South San Francisco, California, USA
700    1_
$a Gullick, Bryan $u BioAgilytix Laboratories, Durham, North Carolina, USA
700    1_
$a Durham, Jennifer $u BioAgilytix Laboratories, Boston, Massachusetts, USA
700    1_
$a Rennier, Keith $u Labcorp Drug Development, Greenfield, Indiana, USA
700    1_
$a Nagilla, Pruthvi $u Asher Biotherapeutics, Inc., South San Francisco, California, USA
700    1_
$a Muruganandham, Anamica $u BioAgilytix Laboratories, Durham, North Carolina, USA
700    1_
$a Diaz, Manisha $u Eurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA
700    1_
$a Tierney, Cassandra $u Pfizer Inc, Groton, Connecticut, USA
700    1_
$a John, Kaarthik $u REGENXBIO Inc., Rockville, Maryland, USA
700    1_
$a Valentine, Jenny $u Regeneron Pharmaceuticals, Tarrytown, New York, USA
700    1_
$a Lockman, Timothy $u PPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA
700    1_
$a Liu, Hsing-Yin $u Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
700    1_
$a Moritz, Benjamin $u Charles River Labs, Reno, Nevada, USA
700    1_
$a Ouedraogo, Jean Paul $u Charles River Labs, Senneville, Québec, Canada
700    1_
$a Piche, Marie-Soleil $u Charles River Labs, Senneville, Québec, Canada
700    1_
$a Smet, Muriel $u Sanofi, Ghent, Belgium
700    1_
$a Murphy, Jacqueline $u Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
700    1_
$a Koenig, Kaylyn $u Altasciences Preclinical Seattle LLC, Everett, Washington, USA
700    1_
$a Zybura, Agnes $u Labcorp Drug Development, Greenfield, Indiana, USA
700    1_
$a Vyhlidal, Carrie $u KCAS Bioanalytical and Biomarker Services, Shawnee, Kansas, USA
700    1_
$a Mercier, Jonathan $u Flowmetric Life Sciences, Inc., Spring House, Pennsylvania, USA
700    1_
$a Jani, Niketa $u BioAgilytix Laboratories, Boston, Massachusetts, USA
700    1_
$a Kubista, Mikael $u Institute of Biotechnology Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Birch, Donald $u Altasciences Preclinical Seattle LLC, Everett, Washington, USA
700    1_
$a Morse, Karlin $u Altasciences Preclinical Seattle LLC, Everett, Washington, USA
700    1_
$a Johansson, Oskar $u TATAA Biocenter, Gothenburg, Sweden
773    0_
$w MED00163142 $t The AAPS journal $x 1550-7416 $g Roč. 26, č. 1 (2024), s. 24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38316745 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155759 $b ABA008
999    __
$a ok $b bmc $g 2081281 $s 1216967
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 1 $d 24 $e 20240205 $i 1550-7416 $m The AAPS journal $n AAPS J $x MED00163142
LZP    __
$a Pubmed-20240412
Back

Find record

Citation metrics

Archiving options